Vidofludimus (hemicalcium)

Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR) . Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD) . Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3].

Product Specifications

CAS Number

[1354012-90-0]

Product Name Alternative

4sc-101 (hemicalcium) ; SC12267 (hemicalcium)

UNSPSC

12352005

Hazard Statement

H302-H360-H413

Target

Dihydroorotate Dehydrogenase; FXR; Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vidofludimus-hemicalcium.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O.[Ca].[1/2]

Molecular Formula

C20H18FNO4.1/2Ca

Molecular Weight

375.40

Precautions

P264-P270-P273-P280-P330-P405-P501

References & Citations

[3]Leo R Fitzpatrick, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342 (3) :850-60. |[1]Yanlin Zhu, et al. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590. |[2]Andreas Muehler, et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129.